New Approaches in Continuous BioManufacturing:

Similar documents
Process-scale purification of monoclonal antibodies polishing using Capto Q

Monoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.

Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform

High yield antibody production in a disposable WAVE Bioreactor

The Importance of Developing a High Yield of Product

A new, integrated, continuous purification process template for monoclonal antibodies

Biotechpharma company profile

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

Single Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography

How To Develop A Cell Line

Continuous Chromatography for Monoclonal Antibody Purification from Cell Culture Supernatant

Bioprocessing Media and Buffers Grow with Us

A novel AIEX chromatography medium (resin) to remove IgA and IVIG purification process

Trends in Upstream and Downstream Process Development for Antibody Manufacturing

Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies

MabSelect SuRe. GE Healthcare Life Sciences

Evaluation of an alkali stable Protein A matrix versus Protein A Sepharose Fast Flow and considerations on process scale-up to 20,000L.

Application Note. Purifying common light-chain bispecific antibodies using MCSGP. Summary

Manufacturing processes for

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

Application Note. Separation of three monoclonal antibody variants using MCSGP. Summary

TECHNICAL BULLETIN. HIS-Select Nickel Affinity Gel. Catalog Number P6611 Storage Temperature 2 8 C

Overview of Upstream and Downstream Processing of Biopharmaceuticals

Bringing Downstream Productivity into Phase with Upstream Antibody Production

Affi-Prep Protein A Matrix Instruction Manual

Improving GS-CHO Cell Line Selection: Reducing Time to Clinic

Advances in Biopharmaceutical and Vaccine Manufacturing Plants

Fast Trak Training & Education

HiPer Ion Exchange Chromatography Teaching Kit

Monoclonal antibodies

HiTrap Heparin HP, 1 ml and 5 ml

Cross Flow Filtration Method Handbook

Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals

Recent advances in the purification of IgM monoclonal antibodies

Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development

Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development

BioProcessing J O U R N A L. Trends and Developments in BioProcess Technology. Volume 9 Issue 1 ISSN

Application Note. Increasing the activity of monoclonal antibody isoforms by MCSGP. Summary

A World of Biomanufacturing: Shortages or Global Glut?

Cadence Acoustic Separator

Accelerating drug development to FTIH: Potential of new expression technologies

Introduction to Bioprocessing

Next-Generation Facilities for Monoclonal Antibody Production

Valentina Gualato, Ph.D. Process Development Scientist

QbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins

Workshop on process validation

How To Test For Cleaning Efficiency With A Predictor 96 Well Filter Plate

High-throughput Process Development with PreDictor Plates

THE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS

Choose your optimal tools for protein studies

EMABling Antibody Production Platform

Biomanufacturing Vision for the Future

POROS CaptureSelect affinity columns for highspeed quantification of IgG Fc fusion proteins

The market for therapeutic monoclonal antibodies

INSTRUCTIONS Edition AC

Biopharmaceutical Process Evaluated for Viral Clearance

Luca Romagnoli, Ph.D. Business Development Manager

Protein Synthesis and Purification: Microbial Versus Mammalian Systems

Application Note USD3013. Monoclonal Antibody Production in Suspension CHO Culture Using Single-Use PadReactor Mini Bioreactor

Building a business case for a fully continuous biomanufacturing platform

KMS-Specialist & Customized Biosimilar Service

Data File. Sephadex G-25 media and pre-packed columns. Introduction. Sephadex G-25 Bead structure. Desalting/buffer exchange and gel filtration

Guide to Reverse Phase SpinColumns Chromatography for Sample Prep

SCANTIBODIES Laboratory, Inc. Contract Monoclonal Antibody Production

His GraviTrap. GE Healthcare. Operation

Exciting Trends in Bioprocessing

Application Note. USD 2995 (a) High Throughput Regeneration Study on MEP HyperCel Mixed-Mode Sorbent on ScreenExpert RoboColumns u

1. Introduction to Expanded Bed Adsorption

Efficient Multi-Well Protein Purification Strategies

Mab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation.

RESOURCE Q, 1 ml and 6 ml RESOURCE S, 1 ml and 6 ml

Vaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010

Aurum Ion Exchange Mini Kits and Columns. Instruction Manual

MLX BCG Buccal Cell Genomic DNA Extraction Kit. Performance Characteristics

Application Guide... 2

XPure. Simulated Moving Bed. System for Chromatography and Ion exchange applications. Better solutions for your purification needs

Technology Transfer of CMC Activities for MAb Manufacturing ge healthcare (

Technologies for Monoclonal Antibody Production

Triskel: a strategic consulting firm for biopharmaceutical companies

Chromatin Immunoprecipitation

Transgenic technology in the production of therapeutic proteins

His Mag Sepharose excel. Ni Sepharose excel. HisTrap excel. gelifesciences.com

Customer Application Brief. Filtration Processes Applied in Therapeutic Monoclonal Antibody Production. Bioprocess, Biologicals, & Pharmaceutical

High-Throughput 3-D Chromatography Through Ion Exchange SPE

Purification of GST-tagged Proteins

Oasis HLB Cartridges and 96-Well Plates

Transforming a ChromLab Software 2-D Purification Template into an Automated Multidimensional (Multi-D) Purification Workflow An Instructional Guide

Blue Sepharose 6 Fast Flow

Classic Immunoprecipitation

SYNERGISTIC APPLICATION OF ADVANCED PRIMARY AND SECONDARY WASTEWATER TREATMENT SYSTEMS

Manufacturing process of biologics

Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates

Wastewater Reuse. Typical treated wastewater is:

Mustang Q XT Chromatography Capsules

Guidance for Industry. Monoclonal Antibodies Used as Reagents in Drug Manufacturing

POROS CaptureSelect affinity columns for rapid, small-scale purification and sample preparation of recombinant proteins

Genomic DNA Extraction Kit INSTRUCTION MANUAL

Aspects of industrial purification of peptides using large-scale chromatography. Lars Andersson and Jonas Persson

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

THE His Tag Antibody, mab, Mouse

Transcription:

New Approaches in Continuous BioManufacturing: Continuous XD cell cultures (around 100 mln cells/ml) coupled to the Rhobust EBA integrated clarification and purification technology Gerben Zijlstra, PhD Sr. Scientist DSM Biologics, The Netherlands

Outline Introduction DSM Biologics DSM XD Technology RHOBUST Expanded Bed Adsorption (EBA) Technology Continuous XD coupled to RHOBUST EBA Principle Continuous XD examples Rhobust EBA on continuous XD harvest Concluding Remarks 1

DSM Biologics: Who are we? Part of DSM: A Leading Global Life Sciences & Material Sciences Company Active in 50 countries & 5 continents at over 200 locations 2012 revenue > 9 billion ~23,000 employees DSM Biologics Manufacturing Locations The Netherlands and Australia DSM Biologics Services Contract manufacturing for mammalian cell culture: From development to commercial manufacturing cgmp for all clinical phases & market supply Regulatory support Global reach Proprietary Process Technologies: XD - intensifying upstream process technology RHOBUST - direct capture technology Page 2

XD Technology Very high-density mammalian processes Increased bioreactor output & yield per volume 5 15 fold High & Consistent product quality Reduced capital expenditure requirements Lower scale-up risk XD is a registered trademark of DSM Page 3

XD : Proprietary Process Intensification Cell Culture Modes Fed Batch Feed concentrate Build up Metabolites Osmo increase Changing environment Reducing cell viabilities Concentrated Harvest batch identification XD Medium Feed Wash out Metabolites No Osmo increase Constant environment High cell viabilities Concentrated Harvest batch identification Perfusion Medium Feed Wash out Metabolites No Osmo increase Constant environment High cell viabilities Dilute harvest Large harvest XD Process Page 4

XD : Process Intensification Scale-up - PER.C6 ; Viable cell count 1000 2L XD reference 50L XD run #1 50L XD run #2 VCD (*10E6 cells/ml) 100 10 1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 0 Time (day) Page 5

XD scale up Scale-up - PER.C6 ; Product IgG 100 2L XD reference 50L XD run #1 50L XD run #2 17.05 20.6 21.4 IgG (g/l) 10 1 5 6 7 8 9 10 11 12 13 Time (day) Page 6

XD : Process Intensification Bioreactor Set-up Page 7

Preferred retention system: TFF Page 8 Fully disposable, simple operation, robust, flexible filter choice

DSM RHOBUST Technology Direct product capture Reduced unit operations From 3 to 1 Higher yields Proven scalability Reduced labor cost & process time Suitable for recombinant proteins, antibodies, vaccines Tungsten carbide incorporated in the agarose bead Page 9

RHOBUST Direct Capture Technology Page 10

RHOBUST in Action with the XD Harvest Equilibration Cell wash out XD Harvest ~150x10 6 cell/ml First cell breakthrough Wash RHOBUST 1 step! Complete cell breakthrough Elution Post-Protein A intermediate Page 11

RHOBUST experiments with XD Harvest Results Fed-batch and classical Protein-A packed bed vs. XD and RHOBUST Protein-A: Yield (%) Purity (%) HCP (ug/mg Mab) DNA (ng/mg Mab) Protein A (ppm) Fed-batch, clarification, Protein-A Packed Bed > 85 > 95 1 15 (n=15) 23-49 (n=2) 9-12 XD, Protein-A RHOBUST > 90 > 95 0.3-23 (n=19) 3.7-121 (n=6) 4-14 With high cell viabilities ~10% higher yield HCP, DNA & res.protein A After column in normal range Page 12

Outline Introduction DSM Biologics DSM XD Technology RHOBUST Expanded Bed Adsorption (EBA) Technology Continuous XD coupled to RHOBUST EBA Principle Continuous XD examples Rhobust EBA on continuous XD harvest Concluding Remarks 13

Continuous XD - Rhobust principle Medium Diluted Waste Stream Waste Product eluate Low ph treatment Waste Elution buffer 2-8 C Product/Cell Bleed Concentrated Product Bleed Tungsten carbide incorporated in the agarose bead XD Bioreactor Cell/Product Bleed Rhobust EBA+Low ph Low ph treated EBA bulk Page 14

Continuous XD example 1: Myeloma - IgG Page 15 Continuous XD cultures with Myeloma cells producing highly potent IgG at around 60 mln cells/ml.

Continuous XD example 1: Myeloma - IgG Page 16 The Qp (slope of cumulative titer) was constant at maximum Qp.

Continuous XD example 2: CHO - IgG Page 17 Continuous XD cultures with CHO cells producing Biosimilar IgG at around 100 mln cells/ml.

Continuous XD example 2: CHO - IgG Page 18 The IgG titer in the product was bleed around 2.5 g/l in production phase.

Continuous XD example 4: PER.C6 IgG Page 19 Continuous XD with IgG producing PER.C6 cells at around 100 mln cells/ml. IgG titer in the bleed 4.5-5 g/l

Rhobust EBA example 2: IgG Page 20 An continuous XD bioreactor processed with eight Rhobust EBA runs (6 cell bleeds and 2 final bioreactor harvest loads). Product recovery, averaging at 93% was substantially higher compared to the combination of dead-end filtration and fixed bed Protein-A.

Rhobust EBA example 2: IgG Residual DNA and HCP were within normal ranges and comparable to packed bed values. Page 21 Aggregate levels and relative potency were relatively constant throughout the run.

22 Concluding remarks Advantages Continuous XD technology coupled to Rhobust EBA USP (Continuous XD cell culture): Functional advantages: Robust, stable performance: Stable growth rate by Cell bleed Very high Productivity: Very high cell density x Maximum Qp No product loss: Bleed = Product! Constant Quality: High viability & Constant environment Operational advantages: Concentrated product flow: Harvest holding point possible DSP (Rhobust EBA Clarification / Capture): Functional advantages: Very high Recovery: Single unit operation, Concentrated product flow Very high Purity: Optimized Rhobust EBA Operational advantages: Easy to use, no column packing, air bubbles and precipitates no problem One step clarification and capture

Acknowledgements: R&D Scientist team DSM-B Gerben Zijlstra Olaf Mol Dick Smit Jurjen de Jong Piet den Boer Mark Doeven Erik kremer Henk van Urk Jaco van der Merwe R&D Director Fritjof Linz GMP Process Technologist team Imre Akkerman Maria Perlasca Mark Dressen Harriet van der Molen GMP OPS Manager Esther Heuberger All Technicians involved in this work Page 23

Thank you Gerben.Zijlstra@DSM.com

25 Outline Introduction DSM Biologics DSM XD Technology RHOBUST Expanded Bed Adsorption (EBA) Technology Continuous XD coupled to RHOBUST EBA Principle Continuous XD examples Rhobust EBA on continuous XD harvest Concluding Remarks

Page 26 Proprietary Technologies vs. Classical Concept Optimize individual Unit Operations Process Intensification & Process Integration

Page 27 XD : Process Intensification Bioreactor Set-up Concentrated Product Bleed

Page 28 XD : Process Intensification Scaled-up in different 50 L Single Use Bioreactors

Scale-up: 200 L XD Results 200 L XD run with CHO cell line performed in PD with 2L satellite run under equal conditions 200 L XD run performed in standard Sartorius STR bioreactor (only increased size side ports) Successful scale-up to equal cell densities (130 mln cells/ml in 200 L) No oxygen or other limitation observed 14,00 12,00 200L XD Biomass corrected titer (Nephelometer) 2L P23037 Titer similar to satellite run > 10 g/l Specific productivity the same Titer (g/l) 10,00 8,00 6,00 4,00 2,00 0,00 0,00 100,00 200,00 300,00 400,00 500,00 600,00 700,00 800,00 900,00 1000,00 IVC Page 29

30 Outline Introduction DSM Biologics DSM XD Technology RHOBUST Expanded Bed Adsorption (EBA) Technology Continuous XD coupled to RHOBUST EBA Principle Continuous XD examples Rhobust EBA on continuous XD harvest Concluding Remarks

Page 31 Rhobust : In action Elution of concentrated product

32 RHOBUST GMP column (30 cm diameter) and MabDirect ProteinA adsorbent GMP EBA column 30cm diameter 20cm - 60cm settled bed EBA level monitoring and control (ultrasound) Low pressure system RFD (variable speed) Disposable flow path UV, flow, conductivity, pressure, temperature, ph using AktaReady Operational MabDirect ProteinA RSF available

Rhobust EBA on Cont. XD example 1 Cell density: 60-90 million cells/ml (viability >80%) Antibody titer: 1.3 g/l Comparison: MabDirect proteina EBA vs. clarification & protein A packed bed chromatography Load ratio: Approx. 22 mg IgG/mL settled bed (both protein A resins) Process Overall yield (%) Purity HP-SEC (%) Buffer use (CV) Process time lab-scale 1 (hours) Process time Manufacturing scale, estimated 2 (hours) Rhobust EBA 82 99.6 67 6.8 6.8 Clarification & ProteinA packed bed 70 99.4 118 12.5 18.5 1 Clarification and chromatographic process (ph treatment, filtration and filling not included) 2 Clarification manufacturing scale will take 6-8 hours (includes dilution, pre-rinse, filtration, post-rinse) 33

34 Concluding remarks Advantages RHOBUST technology Operational: Easy to use, no column packing Can deal with air bubbles and precipitated material One step clarification and capture No separate clarification 8-hour time reduction of process time Suitable for other high viscosity feed streams (incl. microbial and yeast). Development and Scale-up Reduced-scale model available (1 cm and 2 cm column + AKTA Explorer) Scalable concept: Pilot scale unit (10 60 cm columns + Rhobust Flex or AKTA Ready) Fully automated GMP unit (10 60 cm colums + AKTA Ready)» 30cm-diameter EBA column with floating piston» EBA level monitoring and control (ultrasound)» Disposable flow path and in process monitoring in place (AKTA Ready) Resins and ligands: Available Resins: MabDirect ProteinA, MabDirect MIMO, FastLine SP Large ligand library (Incl): IMAC, Q, DEAE

Continuous XD example 3: PER.C6 Rec. Page 35 Continuous XD culture with PER.C6 cells producing recombinant protein (> 300 kd). Discrete intermittent product bleeds were taken for subsequent DSP

Page 36 Principle of the Kremer Method A one step flow-through intermediate purification and polishing procedure, which can optionally be followed by virus filtration. Benefits: One unit operation for 2 chromatography steps Standard dual pump chromatography systems required Product in flow-through, impurities bind ( small resin volumes) No intermediate storage Good removal of aggregates and HCPs The Kremer method has successfully been applied to post Rhobust intermediate yielding very similar purity as classical DSP.

Rhobust EBA from Cont. XD example 1 mau 3500 3000 2500 2000 1500 10.0 8.0 6.0 OD 280 ph Fractions F3- Load F4 - Wash 1 F5 Wash 2 F6 - Elution F7 - Strip F8 - Cleaning 1000 500 4.0 0 F F3 F4 F5 F6 F7 F8 500 1000 1500 Volume (ml) 2.0 37